Literature DB >> 12200383

A molecular compendium of genes expressed in multiple myeloma.

Jaime O Claudio1, Esther Masih-Khan, Hongchang Tang, Jason Gonçalves, Michael Voralia, Zhi Hua Li, Vincent Nadeem, Eva Cukerman, Ofelia Francisco-Pabalan, Choong Chin Liew, James R Woodgett, A Keith Stewart.   

Abstract

We have created a molecular resource of genes expressed in primary malignant plasma cells using a combination of cDNA library construction, 5' end single-pass sequencing, bioinformatics, and microarray analysis. In total, we identified 9732 nonredundant expressed genes. This dataset is available as the Myeloma Gene Index (www.uhnres.utoronto.ca/akstewart_lab).Predictably, the sequenced profile of myeloma cDNAs mirrored the known function of immunoglobulin-producing, high-respiratory rate, low-cycling, terminally differentiated plasma cells. Nevertheless, approximately 10% of myeloma-expressed sequences matched only entries in the database of Expressed Sequence Tags (dbEST) or the high-throughput genomic sequence (htgs) database. Numerous novel genes of potential biologic significance were identified. We therefore spotted 4300 sequenced cDNAs on glass slides creating a myeloma-enriched microarray. Several of the most highly expressed genes identified by sequencing, such as a novel putative disulfide isomerase (MGC3178), tumor rejection antigen TRA1, heat shock 70-kDa protein 5, and annexin A2, were also differentially expressed between myeloma and B lymphoma cell lines using this myeloma-enriched microarray. Furthermore, a defined subset of 34 up-regulated and 18 down-regulated genes on the array were able to differentiate myeloma from nonmyeloma cell lines. These not only include genes involved in B-cell biology such as syndecan, BCMA, PIM2, MUM1/IRF4, and XBP1, but also novel uncharacterized genes matching sequences only in the public databases. In summary, our expressed gene catalog and myeloma-enriched microarray contains numerous genes of unknown function and may complement other commercially available arrays in defining the molecular portrait of this hematopoietic malignancy. GenBank Accession numbers include BF169967-BF176369, BF185966-BF185969, and BF177280-BF177455.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200383     DOI: 10.1182/blood-2002-01-0008

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

Review 1.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

Review 4.  Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.

Authors:  N Lendvai; A D Cohen; H J Cho
Journal:  Bone Marrow Transplant       Date:  2015-03-09       Impact factor: 5.483

Review 5.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 6.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.

Authors:  Casey J Fox; Peter S Hammerman; Ryan M Cinalli; Stephen R Master; Lewis A Chodosh; Craig B Thompson
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

9.  Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Authors:  Véronique Marsaud; Guergana Tchakarska; Geoffroy Andrieux; Jian-Miao Liu; Doulaye Dembele; Bernard Jost; Joanna Wdzieczak-Bakala; Jack-Michel Renoir; Brigitte Sola
Journal:  Mol Cancer       Date:  2010-05-10       Impact factor: 27.401

Review 10.  Annexin A2 system in human biology: cell surface and beyond.

Authors:  Min Luo; Katherine A Hajjar
Journal:  Semin Thromb Hemost       Date:  2013-03-12       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.